- |||||||||| PBF-677 / Palobiofarma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ADENOIBD: Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (clinicaltrials.gov) - Jan 13, 2022 P2a, N=34, Completed, We introduced the technique suitable for observing A3R expression, small molecule competition monitoring, and confirmation of binding to A3AR of novel compounds even in native conditions. Recruiting --> Completed | N=50 --> 34 | Trial completion date: Oct 2021 --> May 2021 | Trial primary completion date: Aug 2021 --> May 2021
- |||||||||| PBF-677 / Palobiofarma
Trial completion date, Trial primary completion date: ADENOIBD: Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (clinicaltrials.gov) - Sep 19, 2020 P2a, N=50, Recruiting, These findings open a novel therapeutic opportunity in liver cancer with minute CBD concentrations and low content of psychotropic THC fraction . Trial completion date: Dec 2020 --> Oct 2021 | Trial primary completion date: Jun 2020 --> Aug 2021
|